CN Patent

CN114685502A — 作为kras-g12c抑制剂的螺环类化合物

Assigned to Suzhou Youli Biomedical Technology Co ltd · Expires 2022-07-01 · 4y expired

What this patent protects

本发明涉及式I所示的作为KRAS‑G12C抑制剂的螺环类化合物，其可以制备用于治疗KRAS G12C介导的肿瘤的药物。

USPTO Abstract

本发明涉及式I所示的作为KRAS‑G12C抑制剂的螺环类化合物，其可以制备用于治疗KRAS G12C介导的肿瘤的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN114685502A
Jurisdiction
CN
Classification
—
Expires
2022-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Youli Biomedical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.